US OptionsDetailed Quotes
MNKD240719C5000
- 0.66
- +0.01+1.54%
15min DelayClose Jul 19 16:00 ET
0.75High0.65Low
0.75Open0.65Pre Close148 Volume491 Open Interest5.00Strike Price10.21KTurnover0.00%IV-0.88%PremiumJul 19, 2024Expiry Date0.71Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma8.65Leverage Ratio--Theta--Rho--Eff Leverage--Vega
MannKind Stock Discussion
Sign in to post a comment
I continue to hold a position in $MannKind(MNKD.US$ which is doing well. The company has a focus on metabolic diseases. I plan to sell the contracts in September (or when they hit my target percentage.) The shares I will hold for the time being, but may sell in favor of a basket such as the $Roundhill GLP-1 & Weight Loss ETF(OZEM.US$ ETF, depending whether MNKD continues to have attractive financials and whether I am willing to pay the management fee.
#Trading Journal
#Trading Journal
2
1
At 30% profit on calls, I will begin selling the contracts. The shares are a longterm hold and candidate for writing contracts.
4
Added to this position on a recent dip. Revenue and profit growth are such that I think this company may continue to perform over time (~34% annual growth past 5 years,) and be reflected in the share price.
3
I posted my shares position earlier and added to it today. Am including contracts as well as the ticker is on the move!
I am sharing positions that are new or currently active vs simply closed for profit in hopes it helps others with DD.
I am sharing positions that are new or currently active vs simply closed for profit in hopes it helps others with DD.
4
A newer position that I’ve been scaling into. Solid pipeline, and potential catalysts upcoming. I hold shares and calls.
2
Another position that I started today. A biopharma with a deep and promising pipeline.
2
Despite MannKind's share price surge, its P/S ratio is low due to a bleak revenue outlook. Shareholders accept this, anticipating no future revenue surprises. A turn of luck is needed for a higher P/S.
Analysts' forecasts reveal that MannKind Corporation's inferior revenue outlook is contributing to its lower P/S ratio. Shareholders accept this, cognizant that future revenue may not meet expectations, hence posing a hindrance for the share price at these levels.
MannKind's progress is recognized by the market and worth investor examination. However, two warning signs warrant attention. Strong share price momentum suggests opportunity.
1
$MannKind(MNKD.US$
need to find out more
need to find out more
1
No comment yet
I Am 102927471 :